Talaris Therapeutics Halted, News Pending
Talaris Therapeutics (TALS) Halted, News Pending
Buy
or
Talaris Therapeutics News & Analysis
-
-
Talaris Therapeutics Announces Leadership Transition
Talaris Therapeutics, Inc. (Nasdaq: TALS), today announced the appointment of Mary Kay Fenton as interim Chief Executive Officer and President effective as of today. Ms. Fenton, who will...
-
H.C. Wainwright downgrades Talaris Therapeutics to Neutral
A H.C. Wainwright analyst downgraded Talaris Therapeutics (NASDAQ: TALS) from Buy to Neutral with a price target of $No data. Prior to this rating, Talaris Therapeutics had 3 buy ratings, 2...
-
Talaris Therapeutics Earnings beat, Revenue Inline In Q3
Investing.com - Talaris Therapeutics reported on Thursday third quarter {{erl-1173019||earnings that beat analysts' forecasts and revenue that was inline with expectations. Talaris...
-
Talaris Therapeutics, Inc. Tops Q2 EPS by 2c
Talaris Therapeutics, Inc. (TALS) reported Q2 EPS of ($0.44), $0.02 better than the analyst estimate of ($0.46).
-
U.S. shares higher at close of trade; Dow Jones Industrial Average up 1.05%
Investing.com – U.S. equities were higher at the close on Friday, as gains in the Utilities, Consumer Services and Telecoms sectors propelled shares higher. At the close in NYSE, the Dow...
-
U.S. shares higher at close of trade; Dow Jones Industrial Average up 1.34%
Investing.com – U.S. equities were higher at the close on Tuesday, as gains in the Basic Materials, Technology and Financials sectors propelled shares higher. At the close in NYSE, the Dow...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
